138 related articles for article (PubMed ID: 37929952)
21. Current Trend in Antiviral Therapy for Chronic Hepatitis B.
Chien RN; Liaw YF
Viruses; 2022 Feb; 14(2):. PubMed ID: 35216027
[TBL] [Abstract][Full Text] [Related]
22. Hemodynamic Effects of Adding Simvastatin to Carvedilol for Primary Prophylaxis of Variceal Bleeding: A Randomized Controlled Trial.
Vijayaraghavan R; Jindal A; Arora V; Choudhary A; Kumar G; Sarin SK
Am J Gastroenterol; 2020 May; 115(5):729-737. PubMed ID: 32079861
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
Yuen MF; Asselah T; Jacobson IM; Brunetto MR; Janssen HLA; Takehara T; Hou JL; Kakuda TN; Lambrecht T; Beumont M; Kalmeijer R; Guinard-Azadian C; Mayer C; Jezorwski J; Verbinnen T; Lenz O; Shukla U; Biermer M;
Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):790-802. PubMed ID: 37442152
[TBL] [Abstract][Full Text] [Related]
24. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.
Niro GA; Ippolito AM; Fontana R; Valvano MR; Gioffreda D; Iacobellis A; Merla A; Durazzo M; Lotti G; Di Mauro L; Andriulli A
J Viral Hepat; 2013 Jul; 20(7):502-9. PubMed ID: 23730844
[TBL] [Abstract][Full Text] [Related]
25. Benefits of nucleos(t)ide analog treatments for hepatitis B virus-related cirrhosis.
Honda K; Seike M; Murakami K
World J Hepatol; 2015 Oct; 7(22):2404-10. PubMed ID: 26464756
[TBL] [Abstract][Full Text] [Related]
26. Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy.
Lin CL; Tseng KC; Chen KY; Liao LY; Kao JH
J Formos Med Assoc; 2020 Oct; 119(10):1483-1489. PubMed ID: 32653388
[TBL] [Abstract][Full Text] [Related]
27. Clinical features of hepatocellular carcinoma with hepatitis B virus among patients on Nucleos(t) ide analog therapy.
Liu L
Infect Agent Cancer; 2020; 15():8. PubMed ID: 32042307
[TBL] [Abstract][Full Text] [Related]
28. Management of HBV and HBV/HDV-Associated Liver Cirrhosis.
Höner Zu Siederdissen C; Cornberg M
Visc Med; 2016 Apr; 32(2):86-94. PubMed ID: 27413725
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy and safety of Entecavir monotherapy switched from Lamivudine combined Adefovir Dipivoxil for chronic hepatitis B virus-related compensated liver cirrhosis].
Lai XJ; Lian JS; Chen JY; Zhang YM; Jia HY; Zheng L; Yang YD
Zhonghua Gan Zang Bing Za Zhi; 2018 Feb; 26(2):113-118. PubMed ID: 29804377
[No Abstract] [Full Text] [Related]
30. Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection.
Viganò M; Invernizzi F; Grossi G; Lampertico P
Aliment Pharmacol Ther; 2016 Oct; 44(7):653-61. PubMed ID: 27528410
[TBL] [Abstract][Full Text] [Related]
31. Extended survival of patients with persistently suppressed hepatitis B transplanted for hepatocellular carcinoma.
Viganò M; Bhoori S; Lampertico P; Donato MF; Iavarone M; Grossi G; Facciorusso A; Caccamo L; Rossi G; Colombo M; Mazzaferro V
Liver Int; 2015 Sep; 35(9):2187-93. PubMed ID: 25809541
[TBL] [Abstract][Full Text] [Related]
32. Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis.
Okada M; Enomoto M; Kawada N; Nguyen MH
Expert Rev Gastroenterol Hepatol; 2017 Dec; 11(12):1095-1104. PubMed ID: 28752768
[TBL] [Abstract][Full Text] [Related]
33. A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B.
van Bömmel F; Stein K; Heyne R; Petersen J; Buggisch P; Berg C; Zeuzem S; Stallmach A; Sprinzl M; Schott E; Pathil-Warth A; von Arnim U; Keitel V; Lohmeyer J; Simon KG; Trautwein C; Trein A; Hüppe D; Cornberg M; Lammert F; Ingiliz P; Zachoval R; Hinrichsen H; Zipprich A; Klinker H; Schulze Zur Wiesch J; Schmiedeknecht A; Brosteanu O; Berg T
J Hepatol; 2023 May; 78(5):926-936. PubMed ID: 37062574
[TBL] [Abstract][Full Text] [Related]
34. Switching from tenofovir and nucleoside analogue therapy to tenofovir monotherapy in virologically suppressed chronic hepatitis B patients with antiviral resistance.
Kim DY; Lee HW; Song JE; Kim BK; Kim SU; Kim DY; Ahn SH; Han KH; Park JY
J Med Virol; 2018 Mar; 90(3):497-502. PubMed ID: 29077211
[TBL] [Abstract][Full Text] [Related]
35. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study.
Bruno S; Crosignani A; Facciotto C; Rossi S; Roffi L; Redaelli A; de Franchis R; Almasio PL; Maisonneuve P
Hepatology; 2010 Jun; 51(6):2069-76. PubMed ID: 20196120
[TBL] [Abstract][Full Text] [Related]
36. Association analysis of KIR/HLA genotype with liver cirrhosis, hepatocellular carcinoma, and NUC freedom in chronic hepatitis B patients.
Joshita S; Ota M; Kobayashi H; Wakabayashi SI; Yamashita Y; Sugiura A; Yamazaki T; Tanaka E; Umemura T
Sci Rep; 2021 Nov; 11(1):21424. PubMed ID: 34728722
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis D: A Review.
Negro F; Lok AS
JAMA; 2023 Dec; 330(24):2376-2387. PubMed ID: 37943548
[TBL] [Abstract][Full Text] [Related]
38. [Risk factors for the development of liver cancer in patients with hepatitis B-related liver cirrhosis treated with long-term nucleos(t)ide analogues].
Zang WW; Su MH; Ling XZ; Wang RM; Cao BC; Wu YL; Deng DL; Wei HL; Liang XS; Jiang JN
Zhonghua Gan Zang Bing Za Zhi; 2020 Aug; 28(8):679-685. PubMed ID: 32911907
[No Abstract] [Full Text] [Related]
39. Severe hepatitis B flares with hepatic decompensation after withdrawal of nucleos(t)ide analogues: A population-based cohort study.
Hsu YC; Lin YH; Lee TY; Nguyen MH; Tseng CH; Ho HJ; Kao FY; Lin JT; Wu CY; Wu CY
Aliment Pharmacol Ther; 2023 Aug; 58(4):463-473. PubMed ID: 37341016
[TBL] [Abstract][Full Text] [Related]
40. Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy.
Alshuwaykh O; Daugherty T; Cheung A; Goel A; Dhanasekaran R; Ghaziani TT; Ahmed A; Dronamraju D; Kumari R; Kwong A; Nguyen M; Kim WR; Kwo PY
Hepatol Commun; 2022 Nov; 6(11):3052-3061. PubMed ID: 36004713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
